Organization
Covance Clinical and Peri-approval Services LTD, Milano, Italy
3 abstracts
Abstract
Roginolisib, an oral, highly selective and allosteric modulator of phosphoinositide 3-kinase inhibitor delta (PI3Kδ) in patients with uveal melanoma and advanced cancers.Org: Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (Milan), Italy, U.O.C. Immunoterapia Oncologica Azienda Ospedaliera Universitaria Senese, Siena, Italy, iOnctura SA, Geneva, Switzerland, iOnctura, Geneva, Switzerland, Covance Clinical and Peri-approval Services LTD, Milano, Italy,
Abstract
First-in-human (FIH) phase I dose escalation study (part A) of the first oral allosteric modulator of phosphoinositide 3-kinase inhibitor delta (PI3Kδ) roginolisib in patients with advanced cancer and dose confirmation in uveal melanoma (part B).Org: iOnctura SA, Geneva, Switzerland, iOnctura, Covance Clinical and Peri-approval Services LTD, Milano, Italy, Radiomics, Liege, Belgium,
Abstract
A safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) study with increasing oral doses of glpg1972 administered daily for 29 days shows a strong biomarker effect in patients with KNEE and/or HIP OAOrg: Clinical Development, Late-Stage Development, Oncology R&D, AstraZeneca, Galapagos, Translational Science Galapagos SASU, Crucell Holland, Covance Clinical and Peri-approval Services LTD, Milano, Italy,